A commentary on the efficacy of olanzapine for the treatment . . . Greater improvements in total BPRS score have been reported with olanzapine compared with haloperidol, with patients over 2 times more likely to achieve clinical response (defined as ≥40% improvement from baseline in BPRS total score) with olanzapine (67% vs 29%, respectively; NNT=3) 38 Significantly greater reductions in PANSS positive
The Effects of Olanzapine on the 5 Dimensions of . . . Results: Olanzapine produced a statistically significantly greater reduction in schizophrenic symptoms than haloperidol (p < 05) on total scores on the BPRS and PANSS on each of the 5 factors as well as on almost all items
A Double-blind, Placebo-Controlled Dose-Response Comparison . . . Doses of 5 0, 7 5, and 10 0 mg of IM olanzapine were superior to IM placebo on the PANSS-EC by 30 minutes after the first IM injection, indicating a rapid onset of effect with these doses Intramuscular olanzapine also resulted in greater improvement than IM haloperidol on the ABS (7 5 mg and 10 0 mg) and ACES (10 0 mg)
Olanzapine versus placebo and haloperidol: acute phase . . . In overall symptomatology improvement (Brief Psychiatric Rating Scale [BPRS]-total), Olz-M, Olz-H, and Hal were significantly superior to placebo In positive symptom improvement (BPRS-positive), Olz-M, Olz-H, and Hal were comparable and significantly superior to placebo
Olanzapine Versus Placebo and Haloperidol: Quality of Life . . . Olanzapine at doses of 10 ± 2 5 mg day and 15 ± 2 5 mg day was significantly more effective than placebo in reducing the severity of psychotic symptoms based on improvement in BPRS total and CGI severity scores over a 24-week period in patients with schizophrenia who responded to acute treatment
Olanzapine Versus Placebo in the Treatment of Acute Mania In the primary efficacy analysis, change from baseline to endpoint in total scores on the Young Mania Rating Scale, the olanzapine group experienced significantly greater mean improvement than the placebo group